MarginsXMarginsX
Home › Markets › Health Care › DMRA

Damora Therapeutics Inc. (DMRA)

DMRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$22.50
+4.14% on the day
Market cap
$1.4B
Small cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerDMRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryDenmark
IPO year2020
SEC CIK0001800315
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
71.0 months
$349.7M cash at September 30, 2026
Share count, 1 year
+4564.3%
2025-11-03 to 2026-11-02 · +5608.1% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$222K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern."
10-Q 2026-11-04
Cash and burn$349.7M cash; operating cash flow -$14.8M a quarter.Report 2026-09-30
Shares outstanding61,904,742 (2026-11-02); 1,327,212 a year earlier; 27,112,697 three years earlier. 3y figure adjusted for split (1-for-25 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-25 on 2024-08-30Source 2024-08-30
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-02-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEY Godkendt Revisionspartnerselskab, Copenhagen, Denmark; changed auditors 1 time in 24 months8-K 4.01 2026-04-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $253K, sold $31K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$32.0M-$17.2M$349.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$31.2M-$21.9M$540.5MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2026
2026-03-31
Not filed-$27.8M-$20.6M$532.9MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
Not filed-$200.7M$566K$257.6MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$3.1M-$2.6M$7.6MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$3.4M-$2.2M$10.2MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2025
2025-03-31
Not filed-$2.5M-$2.4M$11.9MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
Not filed-$6.7M-$4.9M$14.2MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-08-10
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-07-20
Latest proxyDEF 14A2026-04-29

Source: SEC EDGAR submissions feed, 353 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.9%
1 month+16.4%
3 months-29.7%
Year to date-6.1%
1 year-22.4%
From 52-week high-36.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NBTXNanobiotix S.A.$28.54-6.90%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier